| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
| |
| |
April 18, 2017 |
|
|
| |
|
|
| |
|
|
|
Compliance4All, Online
2017-06-06
Overview:
FDA policy and goals regarding the 483 response are discussed. Examples of
both good and poor responses are given. Warning Letters and responses are
discussed and the implications of both a good and poor response to a possible
Warning Letter are given.
Why you should attend:
Learn how to respond to FDA 483's and the best way to write the response.
Learn the new policy from FDA regarding how and when to respond. Learn the
best way to respond in case a Warning Letter is issued. Learn what is a
satisfactory response to FDA and what is not.
Areas Covered in the Session:
How to respond to an FDA Form 483
Using the preferred format
The timing of the response
The wording and tone of the response
What to include as attachments
What to include in the response itself
Who Will Benefit:
Manager/Director QA
Manager/Director Regulatory Affairs
Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
|
|
|
|
|
|
|
|
Organized by:
|
|
Compliance4All |
|
|
Invited Speakers:
|
|
Speaker Profile:
John R. Godshalk currently works for the Biologics Consulting Group as a
Senior Consultant. John served as a Senior Review Biochemical Engineer and
Lead cGMP inspector in the Division of Manufacturing and Product Quality at
CBER, FDA. He contributed to formulation of FDA policy.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2017-06-05
|
|
|
|
|
|
|
|
Registration:
|
|
Full Details & Registration Link: http://www.compliance4all.com/control/w_product/~product_id=501115LIVE?channel=hum-molgen_Jun_2017_SEO
|
|
|
E-mail:
|
|
support@compliance4All.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|